ScholarLens Back to search
2017•Annals of OncologyOpen access

Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype

David Páez, Maria Tobeña, Ana Sebio, Julen Fernández-Plana, Marta Martín, A.C. Virgili Manrique, Pau Riera, Ivana Sullivan, Juliana Giraldo Salazar

Open full text 2 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Irinotecan, FOLFIRI, Medicine, Internal medicine, Regimen, Colorectal cancer, Neutropenia, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype — Research Paper | ScholarLens